A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers

Official Title

A Phase 2b, Open-label, Single-arm Study of ZW25 Monotherapy in Subjects With Advanced or Metastatic HER2-amplified Biliary Tract Cancers


This multicentre, open-label, single-arm trial will evaluate the anti-tumour activity of ZW25 (zanidatamab) monotherapy in subjects with human epidermal growth factor receptor 2 (HER2)-amplified, inoperable and advanced or metastatic biliary tract cancer (BTC), including intra-hepatic cholangiocarcinoma (ICC), extra-hepatic cholangiocarcinoma (ECC), and gallbladder cancer (GBC).

Trial Description

Primary Outcome:

  • Confirmed objective response rate (ORR) by independent central review (ICR)
Secondary Outcome:
  • Duration of response (DOR) by ICR
  • DOR at ≥ 16 weeks by ICR
  • Disease control rate (DCR) by ICR
  • Progression-free survival (PFS) by ICR
  • ORR by investigator assessment
  • DOR by investigator assessment
  • DOR at ≥ 16 weeks by investigator assessment
  • DCR by investigator assessment
  • PFS by investigator assessment
  • Overall survival
  • Incidence of adverse events (AEs)
  • Incidence of laboratory abnormalities
  • Maximum serum concentration of ZW25
  • Trough concentration of ZW25
  • Incidence of anti-drug antibodies (ADAs)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society